{
    "id": 26525,
    "fullName": "PTEN R130fs",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PTEN R130fs results in a change in the amino acid sequence of the Pten protein beginning at aa 130 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). R130fs has not been characterized, however, other C-terminal deletion mutants downstream of R130 are inactivating (PMID: 10468583), thus R130fs is predicted to lead to a loss of Pten protein function.",
            "references": [
                {
                    "id": 2371,
                    "pubMedId": 10468583,
                    "title": "The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10468583"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "R130fs",
    "createDate": "05/04/2017",
    "updateDate": "09/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 169563,
        "transcript": "NM_000314",
        "gDna": "chr10:g.(87933146_87933147)",
        "cDna": "c.(388_387)",
        "protein": "p.R130fs",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10771,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 K310R and N550K, PIK3R1 R557_K561delinsQ, and PTEN R130fs in culture, and tumor regression in xenograft models (PMID: 28119489).",
            "molecularProfile": {
                "id": 27769,
                "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs"
            },
            "therapy": {
                "id": 1293,
                "therapyName": "Alpelisib + BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10769,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 K310R and N550K, PIK3R1 R557_K561delinsQ, and PTEN R130fs in culture, and tumor regression in xenograft models (PMID: 28119489).",
            "molecularProfile": {
                "id": 27769,
                "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs"
            },
            "therapy": {
                "id": 5613,
                "therapyName": "BGJ398 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10770,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and induced cell death in an endometrial cancer cell line harboring FGFR2 K310R and N550K, PIK3R1 R557_K561delinsQ, and PTEN R130fs in culture (PMID: 28119489).",
            "molecularProfile": {
                "id": 27769,
                "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs"
            },
            "therapy": {
                "id": 5612,
                "therapyName": "BGJ398 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19930,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, borussertib inhibited proliferation and AKT signaling and increased apoptosis in an endometrial cancer cell line harboring PIK3R1 R557_K561delinsQ and PTEN R130fs in culture (PMID: 30858154).",
            "molecularProfile": {
                "id": 34731,
                "profileName": "PIK3R1 R557_K561delinsQ PTEN R130fs"
            },
            "therapy": {
                "id": 9256,
                "therapyName": "Borussertib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17595,
                    "pubMedId": 30858154,
                    "title": "Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30858154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27764,
            "profileName": "PTEN R130fs",
            "profileTreatmentApproaches": [
                {
                    "id": 13560,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PTEN R130fs"
                },
                {
                    "id": 13558,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PTEN R130fs"
                },
                {
                    "id": 13561,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PTEN R130fs"
                },
                {
                    "id": 13559,
                    "name": "PIK3CB inhibitor",
                    "profileName": "PTEN R130fs"
                },
                {
                    "id": 13562,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PTEN R130fs"
                }
            ]
        },
        {
            "id": 27769,
            "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34731,
            "profileName": "PIK3R1 R557_K561delinsQ PTEN R130fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 169563,
            "transcript": "NM_000314",
            "gDna": "chr10:g.(87933146_87933147)",
            "cDna": "c.(388_387)",
            "protein": "p.R130fs",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}